Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Bayer HealthCare launches phase III trials of finerenone

Bayer HealthCare launches phase III trials of finerenone

4th September 2015

Bayer HealthCare is expanding the clinical development programme for its investigational drug finerenone with the launch of three phase III clinical trials.

The studies will assess the safety and efficacy of the novel oral nonsteroidal mineralocorticoid receptor antagonist in patients with chronic heart failure, and individuals with diabetic kidney disease.

Patients enrolment is expected to begin by the end of the year. The FINESSE-HF study will investigate finerenone compared to eplerenone in more than 3,600 chronic heart failure patients with reduced ejection fraction and type 2 diabetes and/or chronic kidney disease.

The second, FIGARO-DKD, will assess the drug versus placebo in 6,400 patients with the clinical diagnosis of diabetic kidney disease, mainly comprising of patients with high albuminuria.

Finally, FIDELIO-DKD will investigate finerenone in comparison to placebo in 4,800 patients with diabetic kidney disease who mostly have very high albuminuria levels.

Dr Joerg Moeller, member of Bayer HealthCare's executive committee and head of global development, said: "The data we have seen for finerenone to date across the clinical development programme make us very confident to move finerenone forward into phase III across two important indications of high unmet medical need."ADNFCR-8000103-ID-801799598-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.